Logo

John Mattick

Mar 07, 2018

Genomics England has appointed John Mattick as its first CEO. Mattick will join Genomics England in June from Australia's Garvan Institute of Medical Research, which he has led since 2012. Mattick is noted for his scientific contributions to understanding the human genome, specifically his work showing that most of the genome is not evolutionary 'junk' but instead is devoted to an extensive RNA regulatory system that organizes human development. He will continue his academic career while in the UK at the University of Oxford's Green Templeton College, where he has been elected to a senior research fellowship for one day a week.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.